A published abstract ahead of a science meeting next week gave Actelion's ($ATLN) investors a look at its late-stage data for macitentan, a key new therapy for pulmonary arterial hypertension it will depend on to replace its primary product on the market. A 10 mg dose reduced the risk of death by 38% when compared to a rival drug and more than half compared to a placebo, according to a report from Bloomberg. And analysts were encouraged. Jefferies' Peter Welford called the data "impressive. Given that PAH hospitalization is a hard endpoint, and one I think payers will respond to, to reduce that by 50% with the 10-milligram dose I would say is very promising." The drug will be needed to replace Tracleer once it loses patent protection. Story